据了解，田七家化背靠中恒集团技术资源，构建"技术驱动+品牌矩阵"双轮发展模式。在品牌战略方 面，田七家化实施"主品牌+子品牌"的四维品牌矩阵战略：一是核心层"田七"，强化专业药企背书，主 打"三七科技，草本护龈"专家形象；二是场景品牌"田七娃娃"，打造家庭健康护理IP，开发儿童口腔护 理套装等场景化产品；三是区域品牌"建国"，深耕细分领域及区域市场；四是专业品牌"轻松管家""纯 棉时代"，培育其成为专注于垂直领域的护理专业品牌。 在中恒集团管理支持下，田七家化实现了业绩持续增长。2022年至2024年期间，中恒集团日化板块的对 外营业收入达到近26.5%的年复合增长率，"田七"品牌价值评估已达176.29亿元，位列世界品牌实验室 发布的2025年《中国500最具价值品牌》榜单第422位，在行业赛道中稳步发展。 记者从中恒集团（600252）获悉，中恒集团子公司广西田七家化实业有限公司（简称"田七家化"）于近 日在2025年河池市口腔医学会学术年会暨广西民营口腔学术年会上，推出新品三倍护龈因子牙膏，积极 布局口腔医护级专业护理新赛道。 据了解，该牙膏以"循证研究+草本智慧"为理念，依托中恒集团三七提取技术专利， ...

Core Viewpoint - The company reported a 21.78% year-on-year revenue growth for 2024, attributed to increased procurement demand from major clients, new product development, sales channel expansion, and the acquisition of a new subsidiary, Shanenkang [1] Group 1: Financial Performance - The company recorded a goodwill impairment provision of 39.62 million yuan due to the underperformance of Shanenkang, which failed to meet its profit commitments post-acquisition [2] - The acquisition of Shanenkang was completed on April 7, 2024, resulting in a goodwill of 91.01 million yuan, with a significant asset appreciation rate of 656.94% [2][3] - Shanenkang's actual net profit for 2024 was -0.9026 million yuan, leading to a failure in achieving the promised cumulative net profit of 60 million yuan over three years [2][4] Group 2: Goodwill Impairment Testing - The company conducted a goodwill impairment test, determining that the recoverable amount of Shanenkang's asset group was 198 million yuan, indicating a reduction of approximately 69.33 million yuan from the book value [4] - The management based the impairment test on historical gross margin data and market forecasts, adjusting the focus towards high-margin products in the AKK bacteria market [3][4] Group 3: Long-term Investment in Weimeizi - The company reported a long-term equity investment in Weimeizi with a balance of 711 million yuan, resulting in an investment loss of 8.71 million yuan for the reporting period [5] - Weimeizi faced significant challenges due to a decline in offline sales and ongoing shareholder disputes, leading to a substantial increase in impairment provisions from 50.32 million yuan to 138 million yuan [5][6] - The company noted that Weimeizi's marketing expenses increased significantly in 2024 as part of its transformation strategy, but this did not translate into higher revenue [6][7]

Group 1: Recent IPOs - Custom consumer goods manufacturer Maikris successfully listed on NASDAQ, raising approximately $6.5 million by issuing 1.625 million shares, with a market capitalization of $48.96 million [1] - Hong Kong construction subcontractor Masonglory successfully listed on NASDAQ, raising $6 million by issuing 1.5 million shares, with a market capitalization of $70.42 million [2] - Financial printing service provider Rich Sparkle successfully listed on NASDAQ, raising $5 million by issuing 1.25 million shares, with a market capitalization of $45.88 million [3] - Pan-Asian life insurance company FWD Group successfully listed on the Hong Kong Stock Exchange, raising approximately HKD 3.471 billion by issuing 91.3421 million shares, with a market capitalization of HKD 48.362 billion [4] - Shenzhen-based motor control semiconductor supplier FENGCHUANG Technology successfully listed on the Hong Kong Stock Exchange, raising approximately HKD 2.259 billion by issuing 18.7444 million shares, with a market capitalization of HKD 14.888 billion [5] - Beijing-based AMR warehouse robot solution provider Geekplus successfully listed on the Hong Kong Stock Exchange, raising approximately HKD 2.712 billion by issuing 161 million shares, with a market capitalization of HKD 19.223 billion [6] - Beijing-based communication service provider Xunzhong Co., Ltd. successfully listed on the Hong Kong Stock Exchange, raising approximately HKD 413 million by issuing 30.44 million shares, with a market capitalization of HKD 1.785 billion [7] - Wuhan-based private dental service provider Dazhong Dental successfully listed on the Hong Kong Stock Exchange, raising approximately HKD 217 million by issuing 10.8618 million shares, with a market capitalization of HKD 1.022 billion [8] - Hunan-based precision manufacturing solution provider Lens Technology successfully listed on the Hong Kong Stock Exchange, raising approximately HKD 4.768 billion by issuing 262 million shares, with a market capitalization of HKD 102.6 billion [9] Group 2: Upcoming IPOs - Chinese fast-food brand Laoxiangji has re-filed for an IPO on the Hong Kong Stock Exchange, aiming for a main board listing, with a market share of 0.9% in the Chinese fast-food industry for 2024 [10] - Lithium-ion battery separator manufacturer Xingyuan Material has filed for an IPO on the Hong Kong Stock Exchange, being the first in China to master dry unidirectional stretching technology for battery separators, with a global market share ranking first by shipment volume in 2024 [11] Group 3: Market Insights - Despite the announcement of new tariffs by the U.S. on multiple countries, U.S. stock markets have shown resilience, focusing more on corporate earnings and technological innovation rather than tariff changes, supported by stable economic data and expectations of interest rate cuts [12]

Core Viewpoint - The company received an inquiry letter from the Shanghai Stock Exchange regarding its 2024 annual report, prompting a detailed response about its financial performance and customer relationships [1][2]. Financial Performance - The company achieved a revenue of 1.299 billion RMB in 2024, representing a year-on-year growth of 21.78%. The overseas business contributed 784 million RMB, accounting for 60.35% of total revenue [2][3]. - The gross profit margin for overseas business was 25.44%, which is 4.81 percentage points higher than that of domestic business [2][3]. Customer Information - The company provided detailed information on major customers, including transaction amounts and accounts receivable balances for both domestic and overseas clients [3][4]. - The top overseas customer generated sales of 132.93 million RMB in 2024, while the top domestic customer generated sales of 66.34 million RMB [3][4]. Gross Margin Analysis - The difference in gross margins between overseas and domestic sales is attributed to the product mix and pricing strategies. The overseas sales model allows for higher pricing due to the demand for premium products [8][9]. - The gross margin for oral care products overseas is 7.83 percentage points higher than that of domestic sales, while for wet wipes, the difference is 11.4 percentage points [8][9]. Revenue Growth Drivers - The revenue growth is driven by increased customer demand, new product development, and the expansion of sales channels, including the acquisition of Shen'enkang, which contributed to the overall revenue increase [13][14]. - The main categories contributing to revenue growth include oral care products, wet wipes, and probiotics, with oral care products alone generating 843.15 million RMB in 2024, up 16.80% from the previous year [13][14]. Acquisition and Goodwill Impairment - The company acquired 52% of Shen'enkang, which resulted in a goodwill of 91.01 million RMB. However, Shen'enkang did not meet its performance commitments in 2024, leading to a goodwill impairment of 39.62 million RMB [14][15].

2025年7月10日， 杭州舒雅齐医学科技有限公司 宣布完成来自 时代天使集团 的战略投资。此次交易完成 后， 时代天使将持有舒雅齐35%的股份 ，汉斯夫（杭州）医学科技有限公司继续 持有65%的股份 。双方表 示，将在保持品牌独立运营的基础上，实现资源协同，共同探索创新合作模式。 此次战略投资的具体金额未披露。根据公开信息，双方合作的重点在于 强化舒雅齐的医学服务能力，提升其 在新兴市场的服务覆盖与技术支持能力 。 # 关于 舒雅齐 公司产品线包括 "经典版"和"星空版"隐形矫治器 ，分别适用于不同类型的牙齿畸形病例。舒雅齐的产品主要 应用于青少年及成人轻中度牙齿错颌畸形矫治，已在多个新兴市场区域实现规模化应用。 思宇年度活动回顾： 首届全球眼科大会 | 首届全球骨科大会 | 首届全球心血管大会 | 首届全球医美科技大会 即将召开： 2025年7月17日，第二届全球医疗科技大会 杭州舒雅齐医学科技有限公司 成立于2025年4月30日，总部位于浙江省杭州市余杭区，是一家专注于口腔正 畸服务的医疗科技公司。公司主营业务涵盖 正畸类口腔医疗器械 产品的研发、生产和销售，致力于为牙医提 供数字化、高性价比的隐形矫治 ...

暑期来了，想给孩子报个科技培训班，万一遇到虚假宣传，钱退不回来怎么办？ 夏天到了，想办张健身卡塑形，又怕练几天老板"跑路"，钱打水漂？ 牙齿需要进行根管治疗，但是周期比较长，担心钱还没用完店家就关门，退款无路？ 在日常生活中，预付式消费是一种常见的消费模式，但上述"预付金额难追讨""拒绝合理退费"等问题让不少消费者头疼不已，如何破解这一发展困境？ 针对问题频发领域出台专项措施 近年来，预付式消费领域问题频发，出现商家"卷款跑路"、设置"霸王条款"、收款不退等现象，严重损害了消费者的合法权益，也影响了市场的正常秩序。 ▲健身房 今年3月14日，最高人民法院举行新闻发布会，发布了《最高人民法院关于审理预付式消费民事纠纷案件适用法律若干问题的解释》，并于5月1日起正式施 行，为消费者和经营者提供明确的法律指引，助力形成消费和投资相互促进的良性循环。 成都市也正在积极推进相关工作，切实保障消费者权益。当前正值暑假开启节点，成都市相关部门将针对学科类、文化艺术类、体育类、科技类等培训，以 及口腔、美容、健身等领域的预付式消费纠纷出台专项措施，促进行业健康可持续发展，让广大市民朋友消费无忧。 监管护航，预付无忧，预付式消 ...

Group 1 - The Hong Kong IPO market is experiencing a surge, with five companies completing their IPOs on July 9, 2025, marking a significant moment reminiscent of the 2018 tech listing boom [2] - The five companies that went public on the same day include 极智嘉-W, 蓝思科技, FORTIOR, 讯众通信, and 大众口腔, all of which had a successful debut with positive first-day performance [3][4] Group 2 - The first-day performance of the five companies showed gains ranging from 0.22% to 16.02%, with FORTIOR leading at a 16.02% increase, resulting in a market capitalization of approximately 20.8 billion HKD [3] - 蓝思科技 achieved a first-day increase of 9.13%, with a total market value reaching 129.3 billion HKD, while 极智嘉 saw a 5.36% rise, totaling 23 billion HKD in market capitalization [3] - The IPOs were highly sought after, with FORTIOR's public offering receiving 138.26 times subscription, and 蓝思科技's public offering receiving 462.76 times subscription, indicating strong investor interest [3][4] Group 3 - As of July 7, 2025, over 200 companies are in the queue for IPOs in Hong Kong, primarily from the technology, new consumption, and healthcare sectors, reflecting robust market activity [5] - The first half of 2025 saw 44 new listings, a 47% increase from the same period last year, with total fundraising amounting to 1,071 billion HKD, a 699% increase year-on-year [6] - The Hong Kong stock market is expected to maintain its momentum, with projections of around 80 new listings and fundraising between 1,300 billion HKD to 1,500 billion HKD for the entire year [7]

中国经济网北京7月9日讯武汉大众口腔医疗股份有限公司(以下简称"大众口腔"，02651.HK)今日在港交 所上市。截至收盘，该股收报20.70港元，涨幅3.50%。 最终发售价及配发公告显示，大众口腔发售股份数目10,861,800股H股，香港公开发售的的发售股份数 目(经重新分配后调整)1,949,500股H股，国际发售的发售股份数目(经重新分配后调整)8,912,300股H股。 | 發售股份及股本 | | | --- | --- | | 發售股份數目 | 10,861,800 | | 香港公開發售的發售股份數目(經重新分配後調整) | 1,949,500 | | 國際發售的發售股份數目(經重新分配後調整) | 8,912,300 | | 上市後已發行的股份數目 | 49.379.042 | 大众口腔的独家保荐人、独家整体协调人、独家全球协调人、独家账簿管理人及联席牵头经办人为海通 国际，联席牵头经办人为利弗莫尔证券。 大众口腔的最终发售价为20.0港元，所得款项总额为217.24百万港元，扣除基于最终发售价的估计应付 上市开支39.07百万港元后，所得款项净额178.17百万港元。 | 價格資料 | | ...

蓝思科技为全球领先的智能终端精密制造解决方案提供商，尤其在消费电子、智能汽车及新兴科技领域拥有较强的技术实力和市场地位。在此次招股中，蓝 思科技获得资金簇拥，香港公开发售获得462.76倍的认购，全球发售净筹约46.94亿港元。 港交所的锣不够敲了！7月9日，港股IPO市场迎来狂欢日，5家新贵集体敲钟。 当日在港交所挂牌上市的企业多达5家，现场热闹非凡。这5家企业分别为：蓝思科技(06613.HK)、极智嘉-W(02590.HK)、大众口腔(02651.HK)、 FORTIOR(01304.HK)以及讯众通信(02597.HK)。 | 代码 | 名称 | 米幅。 | 现价 | 上市日期� | | --- | --- | --- | --- | --- | | 1 06613 | 蓝思科技 | +3.41% | 18.800 | 20250709 | | 2 02651 | 大众口腔 | +15.75% | 23.150 | 20250709 | | 3 02597 | 讯众通信 | -0.37% | 13.500 | 20250709 | | 4 02590 | 极智嘉-W | -0.71% | 16.680 ...

Core Viewpoint - The Hong Kong Stock Exchange (HKEX) experienced a significant day on July 9, with five companies, including Lens Technology and Geek+, going public simultaneously, marking a historic event with six gongs being struck at once [1][3]. Group 1: Companies Going Public - The five companies listed on July 9 raised a total of approximately HKD 98.21 billion in net proceeds, with Lens Technology leading the fundraising efforts [4]. - Lens Technology's shares were priced at HKD 18.18, achieving a subscription rate of 462.76 times for public offerings and 16.68 times for international offerings, resulting in net proceeds of about HKD 46.94 billion [5][7]. - Geek+ focused on logistics robotics, priced its shares at HKD 16.8, and garnered a subscription rate of 133.62 times for public offerings, raising approximately HKD 25.45 billion [7]. - Xunzhong Communication, a cloud communication service provider, priced its shares at HKD 13.55, achieving a subscription rate of 12.79 times for public offerings, raising around HKD 3.68 billion [7]. - Peak Semiconductor, operating in the semiconductor sector, priced its shares at HKD 120.5, with a subscription rate of 138.26 times for public offerings, raising approximately HKD 21.36 billion [7]. - Dazhong Dental, the only healthcare company among the listings, priced its shares at HKD 20, achieving a subscription rate of 108.25 times for public offerings, raising about HKD 1.78 billion [7]. Group 2: Market Trends and Future Outlook - The IPO market in Hong Kong has been robust, with 44 new listings in the first half of 2025, a 47% increase from 30 in the same period last year, and total fundraising amounting to HKD 107.1 billion, a 699% increase year-on-year [8]. - The Hong Kong IPO market is expected to remain strong in the second half of the year, supported by favorable funding and policy conditions, particularly for technology companies [8]. - As of June 30, 2025, there were 211 companies in the pipeline for IPOs, with over 80% being first-time applicants, primarily in software services, healthcare, and industrial manufacturing [9].